Detalhe da pesquisa
1.
Therapeutic drug monitoring of vedolizumab therapy in inflammatory bowel disease.
J Gastroenterol Hepatol
; 2024 Feb 21.
Artigo
em Inglês
| MEDLINE | ID: mdl-38380724
2.
Molecular Manipulations and Intestinal Stem Cell-Derived Organoids in Inflammatory Bowel Disease.
Stem Cells
; 40(5): 447-457, 2022 05 27.
Artigo
em Inglês
| MEDLINE | ID: mdl-35365825
3.
Therapeutic drug monitoring in inflammatory bowel disease: implementation, utilization, and barriers in clinical practice in Scandinavia.
Scand J Gastroenterol
; 58(1): 25-33, 2023 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-35996928
4.
Trajectories of health-related quality of life and fatigue during vedolizumab therapy in inflammatory bowel disease.
J Gastroenterol Hepatol
; 38(4): 574-583, 2023 Apr.
Artigo
em Inglês
| MEDLINE | ID: mdl-36582016
5.
Patient Satisfaction of Propofol Versus Midazolam and Fentanyl Sedation During Colonoscopy in Inflammatory Bowel Disease.
Clin Gastroenterol Hepatol
; 20(3): 559-568.e5, 2022 03.
Artigo
em Inglês
| MEDLINE | ID: mdl-33371995
6.
Drug Levels Associated With Optimal Discrimination Between Remission and Nonremission and Comparison of Antibody Assays During First Year of Stable Infliximab Maintenance Therapy in Inflammatory Bowel Disease.
Ther Drug Monit
; 44(2): 290-300, 2022 04 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-34387220
7.
A systematic monitoring approach to biologic therapies in inflammatory bowel disease: patients' and physicians' preferences and adherence.
Scand J Gastroenterol
; 57(3): 274-281, 2022 Mar.
Artigo
em Inglês
| MEDLINE | ID: mdl-34779308
8.
Fatigue is a systemic extraintestinal disease manifestation largely independent of disease activity, chronicity, and nutritional deficiencies in inflammatory bowel disease on biologics.
Scand J Gastroenterol
; 57(9): 1051-1057, 2022 09.
Artigo
em Inglês
| MEDLINE | ID: mdl-35412932
9.
Therapeutic thresholds and mechanisms for primary non-response to infliximab in inflammatory bowel disease.
Scand J Gastroenterol
; 55(8): 884-890, 2020 Aug.
Artigo
em Inglês
| MEDLINE | ID: mdl-32631131
10.
Predicting treatment response in ASUC: do we measure systemic severity, organ response or both?
Gut
; 2024 Apr 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-38561214
11.
Absence of Relationship Between Crohn's Disease Activity Index or C-Reactive Protein and Infliximab Exposure Calls for Objective Crohn's Disease Activity Measures for the Evaluation of Treatment Effects at Treatment Failure.
Ther Drug Monit
; 41(2): 235-242, 2019 04.
Artigo
em Inglês
| MEDLINE | ID: mdl-30883516
12.
Colonic Actinomycosis Mimicking Malignant Stenosing Tumors.
Clin Gastroenterol Hepatol
; 21(2): A17-A18, 2023 02.
Artigo
em Inglês
| MEDLINE | ID: mdl-35850409
13.
Mesalazine-Induced Obstructive Intrahepatic and Extrahepatic Bile Duct Inflammation Mimicking Cholangiocarcinoma.
Clin Gastroenterol Hepatol
; 2023 Dec 04.
Artigo
em Inglês
| MEDLINE | ID: mdl-38056799
14.
Outcome of continued infliximab therapy in Crohn's disease patients with response but without remission after one year of infliximab - a retrospective cohort study.
Scand J Gastroenterol
; 53(8): 930-937, 2018 Aug.
Artigo
em Inglês
| MEDLINE | ID: mdl-29987951
15.
Interactions Between Thiopurine Metabolites, Adalimumab, and Antibodies Against Adalimumab in Previously Infliximab-Treated Patients with Inflammatory Bowel Disease.
Dig Dis Sci
; 63(6): 1583-1591, 2018 06.
Artigo
em Inglês
| MEDLINE | ID: mdl-29564674
16.
Reply.
Clin Gastroenterol Hepatol
; 20(4): e912-e913, 2022 04.
Artigo
em Inglês
| MEDLINE | ID: mdl-33965577
17.
Herpes Zoster Meningoencephalitis: A Novel, Rare, Potentially Fatal Side Effect to Tofacitinib.
Am J Gastroenterol
; 117(1): 195-196, 2022 01 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-34983891
18.
Metabonomics uncovers a reversible proatherogenic lipid profile during infliximab therapy of inflammatory bowel disease.
BMC Med
; 15(1): 184, 2017 10 16.
Artigo
em Inglês
| MEDLINE | ID: mdl-29032767
19.
Reply.
Clin Gastroenterol Hepatol
; 19(11): 2456, 2021 11.
Artigo
em Inglês
| MEDLINE | ID: mdl-33338659
20.
Time Course and Clinical Implications of Development of Antibodies Against Adalimumab in Patients With Inflammatory Bowel Disease.
J Clin Gastroenterol
; 50(6): 483-9, 2016 07.
Artigo
em Inglês
| MEDLINE | ID: mdl-26166141